Drug intelligence / Profile preview

dimolegin

Development stage: Phase 3
Lead developer: PharmaDiall
Modality: Small Molecules
Administration: Oral

Overview

Dimolegin is a novel small molecule anticoagulant developed by PharmaDiall. It acts as a direct oral inhibitor of coagulation factor Xa and is designed for the prevention and treatment of thrombotic complications such as venous thromboembolism. The drug has been evaluated in phase 1–3 clinical trials for indications including venous thromboembolism and COVID-19-associated thrombosis. In phase 3 studies, Dimolegin demonstrated higher efficacy compared to enoxaparin (Clexane) in preventing thrombotic events in hospitalized COVID-19 patients. Its once-daily oral dosing offers convenience over injectable anticoagulants[1][2][3][4][5][8][9].

Brand names: Dimolegin
Other names: DimoleginDD217DD-217DD 217217

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on dimolegin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dimolegin.

Explore the full profile